DK1319003T3 - Xanthin-phosphodiesterase V-inhibitorer - Google Patents

Xanthin-phosphodiesterase V-inhibitorer

Info

Publication number: DK1319003T3
Authority: DK; Denmark
Prior art keywords: inhibitors; xanthine phosphodiesterase; phosphodiesterase; xanthine
Prior art date: 2000-09-19

Application number

DK01971092T

Other languages

English (en)

Inventor

Craig D Boyle

Andrew W Stamford

Samuel Chackalamannil

Yuguang Wang

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-19

Filing date

2001-09-17

Publication date

2009-09-28

2001-09-17 Application filed by Schering Corp filed Critical Schering Corp

2009-09-28 Application granted granted Critical

2009-09-28 Publication of DK1319003T3 publication Critical patent/DK1319003T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK01971092T 2000-09-19 2001-09-17 Xanthin-phosphodiesterase V-inhibitorer DK1319003T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23356700P	2000-09-19	2000-09-19
PCT/US2001/028983 WO2002024698A1 (en)	2000-09-19	2001-09-17	Xanthine phosphodiesterase v inhibitors

Publications (1)

Publication Number	Publication Date
DK1319003T3 true DK1319003T3 (da)	2009-09-28

Family

ID=22877764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01971092T DK1319003T3 (da)	2000-09-19	2001-09-17	Xanthin-phosphodiesterase V-inhibitorer

Country Status (29)

Country	Link
US (6)	US6821978B2 (da)
EP (1)	EP1319003B1 (da)
JP (2)	JP4015547B2 (da)
KR (1)	KR100610417B1 (da)
CN (1)	CN1252071C (da)
AR (1)	AR035199A1 (da)
AT (1)	ATE433451T1 (da)
AU (2)	AU9102201A (da)
BR (1)	BR0113953A (da)
CA (1)	CA2421910C (da)
CY (1)	CY1109329T1 (da)
DE (1)	DE60138955D1 (da)
DK (1)	DK1319003T3 (da)
EC (1)	ECSP034519A (da)
ES (1)	ES2326956T3 (da)
HU (1)	HUP0303016A3 (da)
IL (1)	IL154839A0 (da)
MX (1)	MXPA03002361A (da)
NO (1)	NO328753B1 (da)
NZ (1)	NZ524433A (da)
PE (1)	PE20020469A1 (da)
PL (1)	PL205188B1 (da)
PT (1)	PT1319003E (da)
RU (1)	RU2302420C9 (da)
SI (1)	SI1319003T1 (da)
SK (1)	SK3192003A3 (da)
TW (1)	TWI241301B (da)
WO (1)	WO2002024698A1 (da)
ZA (1)	ZA200301863B (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
SI2298769T1 (sl) *	2001-02-24	2014-02-28	Boehringer Ingelheim Pharma Gmbh & Co.Kg	Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
DE60100055T2 (de) *	2001-03-21	2003-07-24	Schwarz Pharma Ag	Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
DE60225556D1 (de) *	2001-07-03	2008-04-24	Novo Nordisk As	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US6869947B2 (en)	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2003024965A2 (en) *	2001-09-19	2003-03-27	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
WO2003042216A1 (en) *	2001-11-09	2003-05-22	Schering Corporation	Polycyclic guanine derivative phosphodiesterase v inhibitors
US20050107394A1 (en) *	2001-12-17	2005-05-19	Ardeschir Ghofrani	Novel use of selective pde5 inhibitors
US20030181461A1 (en) *	2002-01-25	2003-09-25	Lautt Wilfred Wayne	Use of phosphodiesterase antagonists to treat insulin resistance
SI1509525T1 (sl)	2002-05-31	2006-12-31	Schering Corp	Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
CN101538224A (zh) *	2002-05-31	2009-09-23	先灵公司	制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
AU2003249658A1 (en) *	2002-05-31	2003-12-19	Schering Corporation	Xanthine phosphodiesterase v inhibitor polymorphs
EP1521584A1 (en) *	2002-06-17	2005-04-13	Glaxo Group Limited	Purine derivatives as liver x receptor agonists
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) *	2002-08-22	2009-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en)	2002-08-22	2009-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) *	2002-11-21	2004-06-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en)	2003-06-18	2009-07-28	Boehringer Ingelheim International Gmbh	Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
WO2005012303A1 (en) *	2003-07-31	2005-02-10	Schering Corporation	Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
US20070082908A1 (en) *	2003-08-29	2007-04-12	Dainippon Sumitomo Pharma Co., Ltd.	Bicycle pyrazole derivative
WO2005051368A2 (en) *	2003-11-21	2005-06-09	Schering Corporation	Phosphodiesterase v inhibitor formulations
DE10355304A1 (de)	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1689378B1 (en) *	2003-12-02	2009-04-15	Schwarz Pharma Ag	Novel use of peptide compounds for treating central neuropathic pain
NZ548496A (en)	2004-02-14	2010-02-26	Smithkline Beecham Corp	Medicaments with HM74A receptor activity for disorder of lipid metabolism
US7501426B2 (en) *	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) *	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en)	2004-03-13	2008-07-01	Boehringer Ingleheim International Gmbh	Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20100256179A1 (en) *	2004-03-26	2010-10-07	Ucb Pharma Gmbh	Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) *	2004-03-26	2007-02-22	Srz Properties, Inc.	Combination therapy for pain in painful diabetic neuropathy
US7179809B2 (en) *	2004-04-10	2007-02-20	Boehringer Ingelheim International Gmbh	2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) *	2004-05-10	2008-10-21	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
ATE493973T1 (de)	2004-06-04	2011-01-15	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
EP1604655A1 (en) *	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
DE102004030502A1 (de) *	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) *	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) *	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2587499A1 (en) *	2004-11-18	2006-05-26	Schering Corporation	Methods of using pde v inhibitors for the treatment of congestive heart failure
WO2006104870A2 (en) *	2005-03-25	2006-10-05	Schering Corporation	Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
US8648100B2 (en)	2005-04-19	2014-02-11	Takeda Gmbh	Roflumilast for the treatment of pulmonary hypertension
US20070031349A1 (en) *	2005-06-23	2007-02-08	David Monteith	Rapidly absorbing oral formulations of PDE 5 inhibitors
DE102005035891A1 (de) *	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP2009504592A (ja) *	2005-08-10	2009-02-05	スミスクライン・ビーチャム・コーポレイション	選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
US20070043120A1 (en) *	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
EP1754476A1 (en) *	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US9012454B2 (en)	2005-12-09	2015-04-21	Mayo Foundation For Medical Education And Research	Sexual dysfunction
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
SG174054A1 (en)	2006-05-04	2011-09-29	Boehringer Ingelheim Int	Polymorphs
MX2008016000A (es) *	2006-06-15	2009-03-05	Sanol Arznei Schwarz Gmbh	Composicion farmaceutica con efecto anticonvulsivante sinergistico.
EP2057160A1 (en)	2006-08-08	2009-05-13	Boehringer Ingelheim International GmbH	Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
US20100104640A1 (en) *	2007-04-17	2010-04-29	Ratiopharm Gmbh	Pharmaceutical compositions comprising irbesartan
RU2344137C1 (ru) *	2007-07-18	2009-01-20	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА)	Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
BRPI0815405A2 (pt) *	2007-08-17	2015-02-03	Boehringer Ingelheim Int	Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
PE20091730A1 (es) *	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX370599B (es) *	2008-08-15	2019-12-18	Boehringer Ingelheim Int	Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
JP2012502081A (ja)	2008-09-10	2012-01-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh)	2008-12-23	2015-11-21	Boehringer Ingelheim Int	有機化合物的鹽形式
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EA034869B1 (ru)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CN107961377B (zh)	2010-05-05	2022-11-22	勃林格殷格翰国际有限公司	组合疗法
KR20230051307A (ko)	2010-06-24	2023-04-17	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2731947B1 (en)	2011-07-15	2019-01-16	Boehringer Ingelheim International GmbH	Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN105796569A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
JP6615109B2 (ja)	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害薬の医学的使用
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
AU2019287546A1 (en) *	2018-06-14	2021-01-21	Astrazeneca Uk Limited	Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
CN110613717A (zh) *	2019-05-17	2019-12-27	中国医学科学院医药生物技术研究所	一种降低血脂的药物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1938016A1 (de)	1969-07-23	1971-01-28	Fischer Ohg Arzneimittelwerk	Verfahren zur Herstellung von 8-(N-Methyl-N-aethanolamin)-coffein als Arzneimittel gegen Erkaeltungskrankheiten
FR2116302A1 (en)	1970-12-07	1972-07-13	Brun Lab Sa Le	8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity
DE3779374D1 (en)	1986-08-28	1992-07-02	Sandoz Ag	Xanthinderivate.
IT1217190B (it)	1988-04-22	1990-03-14	Recordati Chem Pharm	Composti utili per il trattamento e diagnosi di disfunzioni frettili
US5321029A (en)	1988-11-14	1994-06-14	Beecham-Wuelfing Gmbh & Co.K.G.	Xanthines
GB8906792D0 (en)	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
FR2654935B1 (fr)	1989-11-28	1994-07-01	Lvmh Rech	Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
IL98559A0 (en)	1990-06-21	1992-07-15	Schering Corp	Polycyclic guanine derivatives
GB9020959D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
GB9020921D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
ES2148170T3 (es)	1990-12-21	2000-10-16	Beecham Group Plc	Derivados de xantina.
US5688768A (en)	1991-02-19	1997-11-18	Cor Therapeutics, Inc.	Recombinant thrombin receptor and related pharmaceuticals
US5256766A (en)	1991-02-19	1993-10-26	The Regents Of The University Of California	Recombinant thrombin receptor and related pharmaceuticals
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9210839D0 (en)	1992-05-21	1992-07-08	Smithkline Beecham Plc	Novel compounds
TW252044B (da) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
GB9226532D0 (en)	1992-12-21	1993-02-17	Smithkline Beecham Plc	Compounds
CN1118600A (zh)	1993-02-26	1996-03-13	先灵公司	2-苄基-多环鸟嘌呤衍生物以及制备它们的方法
GB9301192D0 (en)	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
US6143746A (en)	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
GB9423911D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
JPH11503445A (ja)	1995-04-10	1999-03-26	藤沢薬品工業株式会社	ｃＧＭＰ−ＰＤＥ阻害剤としてのインドール誘導体
US5731339A (en)	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
GB9514464D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
US5824683A (en)	1995-11-28	1998-10-20	Schering Corporation	2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
ATE303365T1 (de)	1995-12-28	2005-09-15	Fujisawa Pharmaceutical Co	Benzimidazolderivate
ATE215950T1 (de)	1996-05-10	2002-04-15	Icos Corp	Carbolinderivate
GB9612514D0 (en)	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
EP0863144A4 (en)	1996-08-30	2001-04-11	Kyowa Hakko Kogyo Kk	IMIDAZOCHINAZOLINE
AU4400597A (en)	1996-10-08	1998-05-05	Fujisawa Pharmaceutical Co., Ltd.	Indole derivatives
US5958926A (en)	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5874437A (en)	1996-11-01	1999-02-23	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998038168A1 (en)	1997-02-27	1998-09-03	Tanabe Seiyaku Co., Ltd.	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
EA002057B1 (ru)	1997-04-25	2001-12-24	Пфайзер Инк.	ПИРАЗОЛОПИРИМИДИНОНЫ, КОТОРЫЕ ИНГИБИРУЮТ ЦИКЛИЧЕСКИЙ ГУАНОЗИН-3',5'-МОНОФОСФАТ-ФОСФОДИЭСТЕРАЗУ ТИПА 5 (cGMP PDE5), ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОГО РАССТРОЙСТВА
US6027494A (en) *	1997-06-06	2000-02-22	Autonomous Technologies Corporation	Ablatement designed for dark adaptability
TW453999B (en)	1997-06-27	2001-09-11	Fujisawa Pharmaceutical Co	Benzimidazole derivatives
ES2229510T3 (es)	1997-06-27	2005-04-16	Fujisawa Pharmaceutical Co., Ltd.	Derivados de anillo aromatico.
JP2002509553A (ja)	1997-10-27	2002-03-26	藤沢薬品工業株式会社	ｃＧＭＰ−ＰＤＥ阻害剤としての三環式化合物
US6037346A (en)	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en)	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
JP2001520999A (ja)	1997-10-28	2001-11-06	アシビ，エルエルシー	女性の性的機能不全の処置
US5877216A (en)	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
WO1999021558A2 (en)	1997-10-28	1999-05-06	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE59803108D1 (de)	1997-11-12	2002-03-21	Bayer Ag	2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
CA2302943C (en)	1998-02-19	2007-08-07	Eisai Co., Ltd.	Phthalazine compounds and therapeutic agents for erectile dysfunction
WO1999043679A1 (fr)	1998-02-27	1999-09-02	Kyowa Hakko Kogyo Co., Ltd.	Derives d'imidazoquinazoline
AU2641199A (en)	1998-02-27	1999-09-15	Kyowa Hakko Kogyo Co. Ltd.	Remedies for erectile dysfunction
DE19816857A1 (de)	1998-04-16	1999-10-21	Boehringer Ingelheim Pharma	Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT1371647E (pt)	1998-04-20	2005-10-31	Pfizer	Derivados do acido piridina-3-carboxilico e sua utilizacao como intermediarios
WO1999062905A1 (en)	1998-06-03	1999-12-09	Almirall Prodesfarma, S.A.	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087362A (en)	1999-03-16	2000-07-11	Pentech Pharmaceuticals, Inc.	Apomorphine and sildenafil composition
US6023640A (en)	1999-03-29	2000-02-08	Ross; Jesse	Method contributing to obviating male impotency
CO5271697A1 (es)	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
SI2298769T1 (sl) *	2001-02-24	2014-02-28	Boehringer Ingelheim Pharma Gmbh & Co.Kg	Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
WO2003024965A2 (en) *	2001-09-19	2003-03-27	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
DE60323823D1 (de) *	2002-01-11	2008-11-13	Novo Nordisk As	Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
AU2003249658A1 (en) *	2002-05-31	2003-12-19	Schering Corporation	Xanthine phosphodiesterase v inhibitor polymorphs
CN101538224A (zh) *	2002-05-31	2009-09-23	先灵公司	制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
WO2005012303A1 (en) *	2003-07-31	2005-02-10	Schering Corporation	Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

2001
- 2001-08-28 US US09/940,760 patent/US6821978B2/en not_active Expired - Fee Related
- 2001-09-17 MX MXPA03002361A patent/MXPA03002361A/es active IP Right Grant
- 2001-09-17 SI SI200130934T patent/SI1319003T1/sl unknown
- 2001-09-17 HU HU0303016A patent/HUP0303016A3/hu unknown
- 2001-09-17 DE DE60138955T patent/DE60138955D1/de not_active Expired - Lifetime
- 2001-09-17 BR BR0113953-3A patent/BR0113953A/pt not_active Application Discontinuation
- 2001-09-17 CA CA002421910A patent/CA2421910C/en not_active Expired - Fee Related
- 2001-09-17 SK SK319-2003A patent/SK3192003A3/sk unknown
- 2001-09-17 DK DK01971092T patent/DK1319003T3/da active
- 2001-09-17 PT PT01971092T patent/PT1319003E/pt unknown
- 2001-09-17 RU RU2003111460/04A patent/RU2302420C9/ru not_active IP Right Cessation
- 2001-09-17 KR KR1020037003898A patent/KR100610417B1/ko not_active Expired - Fee Related
- 2001-09-17 AU AU9102201A patent/AU9102201A/xx active Pending
- 2001-09-17 AT AT01971092T patent/ATE433451T1/de active
- 2001-09-17 PL PL361729A patent/PL205188B1/pl not_active IP Right Cessation
- 2001-09-17 CN CNB018159125A patent/CN1252071C/zh not_active Expired - Fee Related
- 2001-09-17 NZ NZ524433A patent/NZ524433A/en not_active IP Right Cessation
- 2001-09-17 WO PCT/US2001/028983 patent/WO2002024698A1/en active Application Filing
- 2001-09-17 IL IL15483901A patent/IL154839A0/xx unknown
- 2001-09-17 EP EP01971092A patent/EP1319003B1/en not_active Expired - Lifetime
- 2001-09-17 AU AU2001291022A patent/AU2001291022B2/en not_active Ceased
- 2001-09-17 ES ES01971092T patent/ES2326956T3/es not_active Expired - Lifetime
- 2001-09-17 JP JP2002529108A patent/JP4015547B2/ja not_active Expired - Fee Related
- 2001-09-18 PE PE2001000936A patent/PE20020469A1/es not_active Application Discontinuation
- 2001-09-18 AR ARP010104405A patent/AR035199A1/es active IP Right Grant
- 2001-09-19 TW TW090123426A patent/TWI241301B/zh not_active IP Right Cessation
2003
- 2003-03-06 ZA ZA200301863A patent/ZA200301863B/en unknown
- 2003-03-18 NO NO20031238A patent/NO328753B1/no not_active IP Right Cessation
- 2003-03-19 EC EC2003004519A patent/ECSP034519A/es unknown
2004
- 2004-02-12 US US10/777,849 patent/US7268141B2/en not_active Expired - Fee Related
- 2004-06-09 US US10/864,218 patent/US20040229885A1/en not_active Abandoned
- 2004-11-16 US US10/990,083 patent/US20050075349A1/en not_active Abandoned
2005
- 2005-03-11 US US11/078,999 patent/US20050182077A1/en not_active Abandoned
2007
- 2007-08-02 JP JP2007202402A patent/JP2007297409A/ja not_active Withdrawn
- 2007-09-10 US US11/852,638 patent/US7531544B2/en not_active Expired - Fee Related
2009
- 2009-08-24 CY CY20091100890T patent/CY1109329T1/el unknown

Also Published As

Publication number	Publication date
PT1319003E (pt)	2009-07-23
US20050182077A1 (en)	2005-08-18
KR100610417B1 (ko)	2006-08-08
HK1056550A1 (en)	2004-02-20
US20040167137A1 (en)	2004-08-26
JP2004509892A (ja)	2004-04-02
US7268141B2 (en)	2007-09-11
NO20031238L (no)	2003-05-14
WO2002024698A1 (en)	2002-03-28
US20050075349A1 (en)	2005-04-07
MXPA03002361A (es)	2003-06-30
SK3192003A3 (en)	2003-08-05
DE60138955D1 (en)	2009-07-23
ES2326956T3 (es)	2009-10-22
US20040229885A1 (en)	2004-11-18
IL154839A0 (en)	2003-10-31
CN1460105A (zh)	2003-12-03
CY1109329T1 (el)	2014-07-02
PL205188B1 (pl)	2010-03-31
CA2421910C (en)	2007-07-10
HUP0303016A2 (hu)	2003-12-29
EP1319003A1 (en)	2003-06-18
ECSP034519A (es)	2003-04-25
US7531544B2 (en)	2009-05-12
ZA200301863B (en)	2004-06-22
PE20020469A1 (es)	2002-06-18
EP1319003B1 (en)	2009-06-10
US6821978B2 (en)	2004-11-23
NZ524433A (en)	2004-09-24
RU2302420C2 (ru)	2007-07-10
US20020169174A1 (en)	2002-11-14
AR035199A1 (es)	2004-05-05
RU2302420C9 (ru)	2008-12-10
HUP0303016A3 (en)	2007-03-28
NO20031238D0 (no)	2003-03-18
AU9102201A (en)	2002-04-02
PL361729A1 (en)	2004-10-04
CA2421910A1 (en)	2002-03-28
CN1252071C (zh)	2006-04-19
JP2007297409A (ja)	2007-11-15
ATE433451T1 (de)	2009-06-15
BR0113953A (pt)	2003-07-22
TWI241301B (en)	2005-10-11
SI1319003T1 (sl)	2009-10-31
KR20030036800A (ko)	2003-05-09
US20080058354A1 (en)	2008-03-06
JP4015547B2 (ja)	2007-11-28
AU2001291022B2 (en)	2007-01-18
NO328753B1 (no)	2010-05-03

Publication	Publication Date	Title
DK1319003T3 (da)	2009-09-28	Xanthin-phosphodiesterase V-inhibitorer
ATE256127T1 (de)	2003-12-15	Betacarbolinderivate als phosphodiesterase- inhibitoren
ATE278690T1 (de)	2004-10-15	Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DK1268480T3 (da)	2004-03-15	8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer
ATE395349T1 (de)	2008-05-15	Polycyclische guanin phosphodiesterase inhibitoren
DE60119492D1 (de)	2006-06-14	Purinderivate
DE60130463D1 (de)	2007-10-25	Pyrimidin-derivate
ATE267836T1 (de)	2004-06-15	Purinderivate
ATE318603T1 (de)	2006-03-15	Pyrrolotriazin kinasehemmer
MA25996A1 (fr)	2003-12-31	Inhibiteurs de phosphodiesterase 4.
DK1272488T3 (da)	2006-07-17	Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE390425T1 (de)	2008-04-15	Xanthin-phosphodiesterase-v-hemmer polymorphe
NO20032291D0 (no)	2003-05-21	Pyrimidinderivater
EP1570847A4 (en)	2008-10-08	PHOSPHODIESTERASE 10A HEMMER
AR028075A1 (es)	2003-04-23	Inhibidores de la peptido-desformilasa
SI1296981T1 (en)	2005-02-28	Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
IDP000027420A (id)	2001-12-20	Inhibitor-inhibitor kinase pirolotriazin